| abstract |
The present invention relates to a pharmaceutical oral formulation for use in the administration of at least two bacteria derived from fecal microbiota to mammals for the treatment and/or prevention of dysbiosis and associated pathologies. The pharmaceutical oral formulation is encapsulated mixture of at least two bacteria derived from fecal microbiota wherein the capsules are coated in a pH responsive polymer composition comprising:n a. 50-70% poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1 by weight of dry polymer, b. 10-30% poly(methacrylic acid-co-ethyl acrylate) 1:1 by weight of dry polymer, c. at least one fatty acid mono-, di- or tri-glyceride ester, or mixtures thereof, d. at least one plasticizer, e. at least one non-ionic emulsifier.n nThe pharmaceutical oral formulation is especially designed to be delivered principally in the ileum and colon and to maintain the sample bacterial viability and diversity. |